ISOS-Implantable Ecosystems of Genetically Modified Bacteria for the Personalized Treatment of Patients with Chronic Diseases

ISOS aims to create a personalized bioreactor using engineered probiotics for on-demand delivery of therapeutic compounds to treat chronic diseases like age-related macular degeneration.

Subsidie
€ 2.433.300
2023

Projectdetails

Introduction

In ISOS, we propose to develop the first biomedical product for the in-situ fabrication and auto-renewed delivery of therapeutic compounds employing complex ecosystems of probiotic genetically engineered bacteria (GEB) integrated in a biomaterial-based bioreactor. ISOS is designed to treat chronic diseases requiring lengthy treatments.

Mechanism of Action

The encapsulated GEB populations produce the therapeutic molecules "on demand," stimulated by the signals of the pathological environment within the patient, i.e., inflammation and/or reactive oxygen species. Bacteria populations interact among themselves to maintain a dynamic equilibrium of the GEB species and to guarantee the survival of the drug-producing GEB as long as the disease persists.

Biosafety and Regulatory Compliance

The GEB ecosystem is designed in such a way that bacteria cannot survive outside of the encapsulating biomaterial, to meet future biosafety and regulatory requirements. The design and configuration of the GEB ecosystem will be personalized for each patient, and it will be done using in-silico tools and synthetic biology.

Proof-of-Concept

As a Proof-of-Concept, we propose to engineer an implantable GEB-based bioreactor for the therapy of the wet form of age-related macular degeneration (wAMD), which is caused by an abnormal production of Vascular Endothelial Growth Factor (VEGF). This Proof-of-Concept will demonstrate the ability of ISOS to replace the repeated intraocular injections of Anti-VEGF molecules (current treatment) with a single ISOS bioreactor that will enhance the therapeutic response and minimize side effects due to the molecular crosstalk between ISOS and the pathological environment.

Future Perspectives

ISOS will establish the principles of a new generation of therapeutic products that will use recombinant probiotic bacteria strains libraries for personalized treatments with rigorous control of local drug production and efficient delivery based on dynamic variation of pathological signals.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 2.433.300
Totale projectbegroting€ 2.433.300

Tijdlijn

Startdatum1-12-2023
Einddatum30-11-2026
Subsidiejaar2023

Partners & Locaties

Projectpartners

  • SILK BIOMED, S.L.penvoerder
  • UNIVERSIDAD COMPLUTENSE DE MADRID
  • UNIVERSITAET LEIPZIG
  • FRAUNHOFER GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG EV
  • ALIEN TT ITALY S.R.L.
  • INDEEP ARTIFICIAL INTELLIGENCE SL
  • UNIVERSITY OF NORTHUMBRIA AT NEWCASTLE

Land(en)

SpainGermanyItalyUnited Kingdom

Vergelijkbare projecten binnen EIC Pathfinder

EIC Pathfinder

INTELLIGENT ENCAPSULATION AND SCREENING PLATFORM FOR PRECISION DELIVERY OF PROBIOTICS TO IMPROVE GUT HEALTH

iNSIGHT aims to develop precision probiotics through innovative microencapsulation for targeted delivery, enhancing gut health and addressing related diseases using advanced technology and personalized treatment.

€ 3.194.343
EIC Pathfinder

Bacteria Biofilm as bio-factory for tissue regeneration

BIOACTION aims to transform biofilm-associated infections into a resource for tissue regeneration using functionalized bio-hydrogels and engineered liposomes, enhancing implant technology and health outcomes.

€ 2.903.862
EIC Pathfinder

On-Demand Bioresorbable OptoElectronic System for In-Vivo and In-Situ Monitoring of Chemotherapeutic Drugs

Develop a bioresorbable chemical sensing system for real-time monitoring of doxorubicin in-vivo, enhancing personalized cancer treatment while eliminating the need for device retrieval surgery.

€ 2.606.250
EIC Pathfinder

PRInted Symbiotic Materials as a dynamic platform for Living Tissues production

PRISM-LT aims to develop a flexible bioprinting platform using hybrid living materials to enhance stem cell differentiation with engineered helper cells for biomedical and food applications.

€ 2.805.403
EIC Pathfinder

Bioorthogonal Implantable Iontronic Switch to Temporally Control the Local Release of Chemotherapeutics

The project aims to develop an implantable bioSWITCH for on-demand drug delivery to tumors, enhancing treatment efficacy and survival rates in pancreatic cancer.

€ 4.420.511

Vergelijkbare projecten uit andere regelingen

ERC Starting...

Microbial Synthetic in vivo Cell Therapy Systems

The MiStiC project aims to develop Clostridium leptum as a stable chassis for localized drug production and delivery, targeting colorectal cancer through engineered biosensors and natural product pathways.

€ 1.499.938
ERC Proof of...

Synergistic Antitumor Activity of Microbiome and OMV-based in situ Vaccination

The project aims to enhance immunotherapy by combining intratumoral injection of engineered bacterial OMVs with oral Bifidobacterium to boost anti-tumor immunity and improve treatment efficacy.

€ 150.000
ERC Consolid...

Redesigning aortic endograft: enabling in-situ personalized aneurysm healing

EPEIUS aims to revolutionize aortic aneurysm treatment by developing a bioengineered, 3D-printed, drug-loaded endograft for early personalized healing through innovative in-vitro models.

€ 1.991.225
ERC Starting...

Engineering of bacteria to see light

EOS aims to develop biohybrid living materials by inducing light sensitivity in motile bacteria for remote drug delivery, using a novel "optobacterial-stimulation" method.

€ 1.500.000
ERC Proof of...

Intelligent Device and Computational Software to Control Mechanical Stress and Deformation for Biological Testing

ISBIOMECH aims to develop a novel intelligent system for controlling mechanical environments in biological testing, enhancing in-vitro therapies and drug discovery for various pathologies.

€ 150.000